Acellular matrix: a biomaterials approach for coronary artery bypass and heart valve replacement.
We have developed a multistep detergent-enzymatic extraction process (involving hypotonic and hypertonic solutions, the detergents octyl-phenoxy-polyethoxyethanol and sodium dodecyl sulfate, as well as DNAse and RNAse) which, while inhibiting autolysis, removes all cells from tissues and, with them, cellular antigens together with lipids and more soluble glycosaminoglycans. What remains is acellular matrix with the structural proteins well conserved and normally arranged. Canine arteries extracted to acellular matrix were implanted as coronary artery bypass allografts in a canine model, without the use of cardiopulmonary bypass, and compared with autogenous saphenous veins. Of nine pilot acellular matrix implants, four were patent, as compared with four of seven saphenous vein grafts. All occlusions in both graft types occurred acutely soon after implantation, with almost all patent grafts followed up for 6 months. The acellular matrix allografts showed no inflammation and only minimal cellular repopulation. This model needs further development, but appears promising for preclinical evaluation. Canine aortic and pulmonic valves extracted to acellular matrix using a modification of our extraction process, eliminating the detergent sodium dodecyl sulfate, were implanted heterotopically as allografts in the left main pulmonary artery in dogs, a location chosen to avoid the need for cardiopulmonary bypass. At 1 month, two-dimensional echocardiography of six implants showed leaflet motion and 3- to 5-mm Hg transvalvular gradients. Explant histology of four valves at 1 month showed no inflammation, cellular repopulation at the base of the valve, and partial endothelialization.(ABSTRACT TRUNCATED AT 250 WORDS)
Wilson
G J
GJ
Centre for Biomaterials, University of Toronto, Ontario, Canada.
Courtman
D W
DW
Klement
P
P
Lee
J M
JM
Yeger
H
H
D000818:Animals; D001705:Bioprosthesis; D001807:Blood Vessel Prosthesis; D001026:Coronary Artery Bypass; D004285:Dogs; D005109:Extracellular Matrix; D006350:Heart Valve Prosthesis; D006351:Heart Valves / Q000473:pathology; D017830:Octoxynol; D010865:Pilot Projects; D012501:Saphenous Vein / Q000637:transplantation; D012967:Sodium Dodecyl Sulfate; D016042:Transplantation, Heterotopic; D014654:Vascular Patency
D012967:Sodium Dodecyl Sulfate; D017830:Octoxynol